Patents for A61P 17 - Drugs for dermatological disorders (106,455)
06/2005
06/22/2005CN1207008C Acne ointment and its preparing process
06/22/2005CN1206999C Spreader cong. compound Triamcinolone acetate, and its prepn. method
06/22/2005CN1206984C Pellets having a core coated with an antifungal and a polymer
06/22/2005CN1206980C Shellfish skin care cosmetics
06/22/2005CN1206979C Face-beautifying and spot-removing cream and its preparing process
06/22/2005CN1206976C Compositions and method for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
06/22/2005CN1206963C Injection for eliminating wrinkles and scar and its prepn
06/21/2005US6909007 Steroidal pharmaceutical compounds
06/21/2005US6908941 Hair and nail treatments using alkanolamines
06/21/2005US6908938 Heterocyclic aromatic compounds useful as growth hormone secretagogues
06/21/2005US6908925 Administering to a candidate subject in need of such treatment, a thus-effective amount of at least one inhibitor of at least one calcium channel for loosening/slackening and/or relaxing cutaneous and/or subcutaneous human skin
06/21/2005US6908920 Pyrimidine derivatives
06/21/2005US6908917 Chromone derivatives as matrix metalloproteinase inhibitors
06/21/2005US6908912 For controlling free-living microorganisms/biofilm growth
06/21/2005US6908889 For shampoos/bath/shower gels for skin/nails/hair comprised of water soluble silicone
06/21/2005US6908616 Composition suitable for immunizing crustaceans by injection against White Spot Syndrome Virus, WSSV, comprising isolated protein consisting of specified amino acid sequence, which delays mortality against WSSV infectivity in crustaceans
06/21/2005CA2309474C New 4-arylpiperidine derivatives for the treatment of pruritus
06/21/2005CA2309473C New 4-arylpiperidine derivatives for the treatment of pruritus
06/17/2005CA2479432A1 Thiazole derivatives
06/16/2005WO2005054213A1 Isoxazole derivative having agonistic activity against peroxisome proliferator-activated receptor
06/16/2005WO2005053718A1 Methods and compositions for treating inflammatory and dermatological conditions
06/16/2005WO2005053680A1 Combination of 2,3-dibenzylbutyrolactone and licochalcone-a
06/16/2005WO2005034883A3 A method of healing skin wounds in mammals and a composition therefor
06/16/2005WO2004071400A3 Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
06/16/2005WO2004060314A3 Treatment of skin wounds using polyenylphosphatidylcholine and alkanolamines
06/16/2005WO1991001624A8 Use of calcium antagonists for treating scars
06/16/2005US20050132428 Cyclic amp phosphodiesterase 4d7 isoforms and methods of use
06/16/2005US20050131236 Central nervous ystem disorders; neurodegenerative disorders; muscle contraction; endocrine diseases
06/16/2005US20050131061 Angiogenesis inhibitors
06/16/2005US20050131047 cardiovascular disorders
06/16/2005US20050131035 Medicaments
06/16/2005US20050131024 Antiinflammatory agents; autoimmune diseases; anticancer agents
06/16/2005US20050131005 4-azasteroid derivatives as androgen receptor modulators
06/16/2005US20050131000 Derivatives of 4-(imidazol-5-yl)-2-(4-sulfoanilino)pyrimidine with cdk inhibitory activity
06/16/2005US20050130998 Central nervous ystem diorders; Alzheimer's disease ; anticancer agents
06/16/2005US20050130996 5-(4-{3-chloro-4-(3-fluorobenzyloxy)-anilino}-6-quinazolinyl)-furan-2-carbaldehyde; selective inhibition of the protein tyrosine kinase activity, minimising side effects
06/16/2005US20050130981 Compounds
06/16/2005US20050130967 3-Substituted-4-pyrimidone derivatives
06/16/2005US20050130965 Inhibitors of p38 kinase
06/16/2005US20050130964 e.g 8-oxa-1-thia-benzo[e]naphtho[3,2-h]azulene-2-carboxylic acid ethyl ester; rheumatoid arthritis
06/16/2005US20050130942 (E)-2,4,6-trimethoxystyryl-4-methoxy-3-aminobenzylsulfone for example; cancer, tumors, multiple sclerosis, Pagets disease; antibody conjugates; target receptor tyrosine kinases and which arrest the Ras/Raf/MEK/ERK kinase cascade
06/16/2005US20050130940 Fungal infections; water soluble phosphate derivatives of triazole drugs such as fluconazole
06/16/2005US20050130935 Combination of a beta-2-adrenoceptor agonists and an aminosugars and their use for the treatment immunomodulatory disorders
06/16/2005US20050130903 Therapeutic agents and methods of use thereof for the modulation of angiogenesis
06/16/2005US20050130902 Upregulate expression of a gene encoding an antioxidative anzyme, such as superoxide dismutase or catalase; neurodegenerative, cardiovascular, cerebral, disorders, trauma, injuries, burns, cancer
06/16/2005US20050130881 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals
06/16/2005US20050130304 Regulation of endogenous gene expression in cells using zinc finger proteins
06/16/2005US20050130145 polynucleotides which identify and encode human secreted proteins (SECP); expression vectors, host cells, antibodies, and agonists; drug screening
06/16/2005US20050129786 Topical composition having undifferentiated plant seed cells and method for using same
06/16/2005US20050129773 Acne; skin disorders; controlling particle sizes
06/16/2005US20050129747 Crosslinking polyoxyalkylene glycol as oxygen carrier; diabetic tissue degradation
06/16/2005US20050129739 Production and use of a polar lipid-rich fraction containing omega-3 and/or omega-6 highly unsaturated fatty acids from microbes, genetically modified plant seeds and marine organisms
06/16/2005US20050129723 Skin care composition that mediates cell to cell communication
06/16/2005US20050129688 Monkey monoclonal antibodies specific to human B7.1 and/or B7.2 primatized forms thereof, pharmaceutical compositions containing, and use thereof as immunosuppressants
06/16/2005US20050129663 Cellular therapy; for promoting axonal regeneration in the CNS, wound healing and treatment of myocardial infarction and spinal cord injury
06/16/2005US20050129625 Aerosolizing dry powder of interleukin-4 receptor with carbohydrage, lipid, buffer, peptide, protein, Group II metal, or oligopeptide excipient; small aerodynamic particle size; dispersion into gas stream to make inhalant
06/16/2005US20050129618 Screening method for active ingredients; contacting stem cell factor SCF-expressing cells with test ingredients, assaying the amount of SCF produced
06/16/2005CA2588874A1 Composition comprising urginea maritima or drimia maritima, laurus nobilis, adiantum capillus-veneris, and persea americana and its use against hair greasiness, hair loss and for promoting hair growth
06/16/2005CA2547887A1 Protein modifier production inhibitor
06/16/2005CA2546959A1 Composition of herbal extracts for the treatment of atopic dermatitis, skin allergic conditions and acne
06/16/2005CA2545140A1 Use of ppar activators in cosmetics and dermatology
06/15/2005EP1541673A1 Novel probiotics for pet food applications
06/15/2005EP1541634A1 Process for the preparation of micronised collagen, and its therapeutic applications
06/15/2005EP1541580A1 Sulfotransferase inhibitors
06/15/2005EP1541576A1 Furoisoquinoline derivative and use thereof
06/15/2005EP1541574A1 Triazaspiro 5.5 undecane derivatives and drugs comprisi ng the same as the active ingredient
06/15/2005EP1541573A1 Novel crystals of triazaspiro 5.5 undecane derivative
06/15/2005EP1541571A1 Bicyclic unsaturated tertiary amine compound
06/15/2005EP1541570A1 Novel physiologically active substance
06/15/2005EP1541563A1 Ccr4 antagonist and medicinal use thereof
06/15/2005EP1541562A1 Novel uracil derivatives and medicinal use thereof
06/15/2005EP1541174A1 Drug or cosmetic
06/15/2005EP1541163A1 Hair growth stimulants for oral use
06/15/2005EP1541162A1 Intravaginal washing agent
06/15/2005EP1541155A1 Carbon dioxide external preparation and material for formation of carbon dioxide external preparation
06/15/2005EP1541152A1 Combination of a phytosterol and/or cholesterol and licochalcone A or an aqueous extract of Glyzyrrhizae inflata radix comprising licochalcone A
06/15/2005EP1541128A2 Cosmetic composition containing derivatives of cinnamic acid and its use
06/15/2005EP1541126A1 Cosmetic and dermatological composition comprising a combination of a green colouring agent and an antiinflammatory agent
06/15/2005EP1541125A1 Spreadable compositions for topical use, a process of making same and uses thereof
06/15/2005EP1539933A2 Methods of organ regeneration
06/15/2005EP1539927A1 Probiotic bacterium: lactobacillus fermentum
06/15/2005EP1539769A1 Bicyclic heteroaromatic compounds as kinase inhibitors
06/15/2005EP1539766A1 Calcitonin gene related peptide receptor antagonists
06/15/2005EP1539763A1 Azaindole kinase inhibitors
06/15/2005EP1539748A1 2-phenylpyridin-4-yl derivatives as alk5 inhibitors
06/15/2005EP1539741A1 2-thio-substituted imidazole derivatives and their use in pharmaceutics
06/15/2005EP1539739A1 Piperidinyl compounds that selectively bind integrins
06/15/2005EP1539732A1 Novel compounds
06/15/2005EP1539729A2 Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
06/15/2005EP1539707A1 Method and compounds for promoting healing and reducing inflammation
06/15/2005EP1539701A1 Caspase inhibitors and uses thereof
06/15/2005EP1539696A2 Process for preparing quinolin antibiotic intermediates
06/15/2005EP1539695A1 N-4-piperidinyl compounds as ccr5 modulators
06/15/2005EP1539693A1 Cannabinoid receptor agonists
06/15/2005EP1539692A1 Furanone derivatives and methods of making same
06/15/2005EP1539683A2 Phenol derivatives and their use as rotamase inhibitors
06/15/2005EP1539679A2 Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use
06/15/2005EP1539678A1 3,4-di-substituted cyclobutene-1, 2-diones as cxc-chemokine receptor ligands
06/15/2005EP1539674A1 Amino-propanol derivatives
06/15/2005EP1539662A1 Cannabinoid receptor ligands